Show simple item record

The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study

dc.contributor.authorArd, Jamy D.
dc.contributor.authorNeeland, Ian J.
dc.contributor.authorRothberg, Amy E.
dc.contributor.authorChilton, Robert J.
dc.contributor.authorLuis, Daniel
dc.contributor.authorCohen, Sarah S.
dc.contributor.authorJohansen, Odd Erik
dc.date.accessioned2024-03-04T15:42:49Z
dc.date.available2025-04-04 10:42:48en
dc.date.available2024-03-04T15:42:49Z
dc.date.issued2024-03
dc.identifier.citationArd, Jamy D.; Neeland, Ian J.; Rothberg, Amy E.; Chilton, Robert J.; Luis, Daniel; Cohen, Sarah S.; Johansen, Odd Erik (2024). "The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study." Diabetes, Obesity and Metabolism 26(3): 950-960.
dc.identifier.issn1462-8902
dc.identifier.issn1463-1326
dc.identifier.urihttps://hdl.handle.net/2027.42/192576
dc.description.abstractAimThe effects of weight loss with a partial or total meal replacement programme (MRP) on atherosclerotic cardiovascular disease (ASCVD) risk factors are not fully understood, in particular in people at higher CV risk. In the 52-week randomized controlled OPTIWIN study in men and women with obesity, meal replacement programme (total for first 26 weeks, partial for the ensuing 26 weeks) with OPTIFAST (OP) resulted in significantly greater weight loss compared with a low-calorie food-based (FB) dietary plan, both as part of a comprehensive lifestyle intervention [OP (n = 135)/FB (n = 138) week 26: −12.4%/−6.0%, p < .001; week 52: −10.5%/−5.5%, p < .001]. Here, we examined effects on ASCVD risk factors and 10-year ASCVD risk.Materials and MethodsParticipants with body mass index 30-55 kg/m2 and age 18-70 years, and not on anti-obesity medications, were recruited. The effects on systolic and diastolic blood pressure (SBP, DBP), lipid parameters and 10-year ASCVD risk were analysed as changes over time using linear mixed models. Subgroup analyses were conducted for changes in SBP, DBP and ASCVD risk by categories of age (<40, 40-59, ≥60 years), baseline SBP (</≥130 mmHg) and sex.ResultsBaseline characteristics were well balanced (OP/FB females 86%/79%, mean age 47/47 years, body mass index 38.4/39.2 kg/m2, 10-year ASCVD risk <5% 87%/74%, dysglycaemia 52%/50%). At week 26, SBP/DBP were significantly reduced with OP versus FB, and a greater proportion achieved BP ≤130/80 mmHg [odds ratio 2.11 (95% confidence interval 1.10, 4.03), p = .024]. All lipid parameters as well as 10-year ASCVD risk were significantly improved with OP versus FB. A similar, but slightly attenuated pattern was observed at 52 weeks. Across subgroups, greater reductions for SBP, DBP and ASCVD risk were generally seen with OP versus FB with quantitatively higher baseline SBP and age, and in men.ConclusionsIn people with obesity at low ASCVD risk, OP significantly reduced cardiovascular risk factors and 10-year predicted risk for ASCVD.
dc.publisherWiley Periodicals, Inc.
dc.publisherBlackwell Publishing Ltd
dc.subject.otherblood pressure
dc.subject.otherheart disease risk factors
dc.subject.otherobesity management
dc.subject.otherbody weight
dc.subject.otherclinical trial
dc.subject.othercaloric restriction
dc.titleThe OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/192576/1/dom15392.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/192576/2/dom15392_am.pdf
dc.identifier.doi10.1111/dom.15392
dc.identifier.sourceDiabetes, Obesity and Metabolism
dc.identifier.citedreferenceEslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020; 73: 202 - 209.
dc.identifier.citedreferenceNoronha JC, Nishi SK, Braunstein CR, et al. The effect of liquid meal replacements on cardiometabolic risk factors in overweight/obese individuals with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2019; 42: 767 - 776.
dc.identifier.citedreferenceMarkovic TP, Proietto J, Dixon JB, et al. The Australian obesity management algorithm: a simple tool to guide the management of obesity in primary care. Obes Res Clin Pract. 2022; 16: 353 - 363.
dc.identifier.citedreferenceWharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020; 192: E875 - e891.
dc.identifier.citedreferenceGarvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016; 22 ( Suppl 3 ): 1 - 203.
dc.identifier.citedreferenceJensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Obesity Society. J Am Coll Cardiol. 2014; 63: 2985 - 3023.
dc.identifier.citedreferenceAmerican Diabetes Association. Obesity Management for the Treatment of type 2 diabetes: standards of medical Care in Diabetes—2021. Diabetes Care. 2020; 44 ( Supplement_1 ): S100 - S110.
dc.identifier.citedreferenceLean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018; 391: 541 - 551.
dc.identifier.citedreferenceAstbury NM, Piernas C, Hartmann-Boyce J, Lapworth S, Aveyard P, Jebb SA. A systematic review and meta-analysis of the effectiveness of meal replacements for weight loss. Obes Rev. 2019; 20: 569 - 587.
dc.identifier.citedreferenceJosse AR, Atkinson SA, Tarnopolsky MA, Phillips SM. Increased consumption of dairy foods and protein during diet- and exercise-induced weight loss promotes fat mass loss and lean mass gain in overweight and obese premenopausal women. J Nutr. 2011; 141: 1626 - 1634.
dc.identifier.citedreferenceHong SH, Choi KM. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences. Int J Mol Sci. 2020; 21 ( 2 ):1-17.
dc.identifier.citedreferenceArd JD, Lewis KH, Rothberg A, et al. Effectiveness of a Total meal replacement program (OPTIFAST program) on weight loss: results from the OPTIWIN study. Obesity. 2019; 27: 22 - 29.
dc.identifier.citedreferenceDPP. The diabetes prevention program (DPP): description of lifestyle intervention. Diabetes Care. 2002; 25: 2165 - 2171.
dc.identifier.citedreferenceKramer MK, Kriska AM, Venditti EM, et al. Translating the diabetes prevention program: a comprehensive model for prevention training and program delivery. Am J Prev Med. 2009; 37: 505 - 511.
dc.identifier.citedreferenceKodama S, Horikawa C, Fujihara K, et al. Meta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus. Am J Cardiol. 2014; 113: 1058 - 1065.
dc.identifier.citedreferenceWhite WB. Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. Am J Hypertens. 1999; 12: 50s - 55s.
dc.identifier.citedreferenceInoue R, Ohkubo T, Kikuya M, et al. Predictive value for mortality of the double product at rest obtained by home blood pressure measurement: the Ohasama study. Am J Hypertens. 2012; 25: 568 - 575.
dc.identifier.citedreferenceAmerican College of Cardiology. ASCVD risk estimator plus. https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/
dc.identifier.citedreferenceLee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010; 42: 503 - 508.
dc.identifier.citedreferenceDearborn Tomazos J, Viscoli C, Amin H, et al. Partial meal replacement for weight loss after stroke: results of a pilot clinical trial. Cerebrovasc Dis. 2023; 1 - 8. doi: 10.1159/000530996
dc.identifier.citedreferenceArmborst D, Metzner C, Bitterlich N, Lemperle M, Siener R. Effect of a weight-loss stabilization following a weight reduction with or without meal replacement on cardiometabolic risk in overweight women. A randomized controlled trial. Int J Food Sci Nutr. 2019; 70: 453 - 466.
dc.identifier.citedreferenceAshley JM, Herzog H, Clodfelter S, Bovee V, Schrage J, Pritsos C. Nutrient adequacy during weight loss interventions: a randomized study in women comparing the dietary intake in a meal replacement group with a traditional food group. Nutr J. 2007; 6: 12.
dc.identifier.citedreferenceZanetti M, Gortan Cappellari G, Burekovi I, Barazzoni R, Stebel M, Guarnieri G. Caloric restriction improves endothelial dysfunction during vascular aging: effects on nitric oxide synthase isoforms and oxidative stress in rat aorta. Exp Gerontol. 2010; 45: 848 - 855.
dc.identifier.citedreferenceWaziry R, Ryan CP, Corcoran DL, et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nat Aging. 2023; 3: 248 - 257.
dc.identifier.citedreferenceKosiborod MN, Bhatta M, Davies M, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023; 25: 468 - 478.
dc.identifier.citedreferenceLingvay I, Mosenzon O, Brown K, et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc Diabetol. 2023; 22: 66.
dc.identifier.citedreferenceLincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. doi: 10.1056/NEJMoa2307563
dc.identifier.citedreferenceHerrington GJ, Peterson JJ, Cheng L, et al. The use of very low-calorie diets in subjects with obesity complicated with nonalcoholic fatty liver disease: a scoping review. Obes Sci Pract. 2022; 8: 510 - 524.
dc.identifier.citedreferenceLewis MC, Phillips ML, Slavotinek JP, Kow L, Thompson CH, Toouli J. Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes Surg. 2006; 16: 697 - 701.
dc.identifier.citedreferenceAfshin A, Forouzanfar MH, Reitsma MB, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017; 377: 13 - 27.
dc.identifier.citedreferenceMechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease, adiposity and Dysglycemia drivers: JACC state-of-the-art review. J Am Coll Cardiol. 2020; 75: 525 - 538.
dc.identifier.citedreferenceKhan SS, Ning H, Wilkins JT, et al. Association of Body Mass Index with Lifetime Risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018; 3: 280 - 287.
dc.identifier.citedreferenceGregg EW, Jakicic JM, Blackburn G, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016; 4: 913 - 921.
dc.identifier.citedreferenceRyan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017; 6: 187 - 194.
dc.identifier.citedreferenceKim JY. Optimal diet strategies for weight loss and weight loss maintenance. J Obes Metab Syndr. 2021; 30: 20 - 31.
dc.identifier.citedreferenceHassapidou M, Vlassopoulos A, Kalliostra M, et al. European Association for the Study of obesity position statement on medical nutrition therapy for the Management of Overweight and Obesity in adults developed in collaboration with the European Federation of the Associations of dietitians. Obes Facts. 2023; 16: 11 - 28.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.